BOSTON, June 18, 2012 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the launch of the PAREXEL MyTrials™ platform, a fully-integrated eClinical solution that simplifies the clinical trial process. Developed by PAREXEL's technology subsidiary Perceptive Informatics, PAREXEL MyTrials is an eClinical platform designed by clinical research experts to provide comprehensive support for the drug development process.
While current technology has promised to accelerate the design and execution of clinical trials, the increased adoption of individual applications creates new integration challenges and workflow inefficiencies. PAREXEL MyTrials addresses these inefficiencies by providing a unified framework built to optimize the benefits of clinical trial technology. Key benefits of PAREXEL MyTrials include:
- Single Sign-On: Access multiple technologies, trials and programs from a single place with a single set of credentials for more efficient workflows and task continuity.
- Convergence: Move seamlessly between applications to achieve true convergence by breaking down silo barriers.
- Scalability: Handle single or multiple studies on a strong and reliable Software-as-a-Service (SaaS) infrastructure and new application integration.
- Reporting: Provide a full and consistent view of the health and progress of trials and programs. Enable effective decision making using comprehensive industry-standard metrics consolidated from multiple applications.
- Collaboration: Facilitate collaboration across the entire study community through a single and secure repository for all of the necessary study information, documentation and training resources, as well as sponsor level libraries, study calendar, training records and discussion forums.
"In recent years there has been an increase in the number of applications for managing the clinical trials process, but these independent systems are not necessarily compatible with each other, for example, forcing users to enter the same data multiple times in different applications. This disrupts optimal workflow and processes, resulting in an unintended loss of productivity," said Dr. Mark A. Goldberg, Chief Operating Officer, PAREXEL. "Sponsors and investigator site users are looking for a unified solution to plan, design and conduct their clinical trial programs. With the availability of PAREXEL MyTrials, users will have a single place to access a comprehensive suite of applications, tools, metrics and reports through full data integration and application convergence. They can expect to realize greater efficiency and conduct more effective trials by harnessing the power of this innovative platform technology and leveraging our integrated product suite, regardless the size, scope or the numbers of trials."
PAREXEL MyTrials provides a single seamless, efficient, scalable technology platform in a SaaS environment. It offers access to a suite of integrated applications, data and information associated with all types of trials and programs, including DataLabs® EDC, DataLabs Designer™, ClinPhone® RTSM, IMPACT® CTMS, ePRO, Medical Imaging, eClinical Metrics reporting, Site-Sponsor collaboration and more.
With PAREXEL MyTrials, users can utilize in their studies one or all of the suite components in a flexible, modular approach. This expandable framework will help enable companies to achieve their corporate eClinical strategy and realize the full potential of their technology investments.
For more information on the PAREXEL MyTrials platform or to view a demo, visit the PAREXEL booth at the 48th Annual DIA 2012 Meeting, June 24-28, in Philadelphia at the Pennsylvania Convention Center, Booth #2224.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 50 countries around the world, and has approximately 11,920 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 as filed with the SEC on May 10, 2012, which "Risk Factors" discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark and PAREXEL MyTrials is a trademark of PAREXEL International Corporation and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.
Georgina Cattaway, Director of Marketing and Public Relations
Kim Leadley/Gene Carozza
Tel: +44 1895 614530
Tel: + 617-502-4300
SOURCE PAREXEL International Corporation
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here